Results 71 to 80 of about 3,972 (148)

Advances in therapeutic approaches to gastric cancer

CA: A Cancer Journal for Clinicians, Volume 76, Issue 5, September/October 2026.
Abstract Gastric cancer remains a leading cause of cancer‐related mortality worldwide, with nearly 1 million new cases diagnosed annually. Despite innovations in diagnosis, most patients still present at advanced stages, contributing to a poor prognosis.
Feng Wang, Zi‐Xian Wang, Yu‐Jing Zhang, Ye He, Jia‐Fu Ji, Yuan‐Fang Li, Xiu‐Juan Qu, Yi Ba, Shu‐Qiang Yuan, Rui‐Hua Xu   +9 more
wiley   +1 more source

Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers

, 2022
PURPOSE Larotrectinib is a highly selective and CNS-active tropomyosin receptor kinase (TRK) inhibitor that has demonstrated efficacy across TRK fusion–positive cancers, regardless of the tumor type.
Liu, Yongmei, Brega, Nicoletta, Rosen, Lee, Lassen, Ulrik N., Drilon, Alexander, Patel, Jyoti D., Shen, Lin, Norenberg, Ricarda, Tan, Daniel S.W., Moreno, Victor, Solomon, Benjamin, Dima, Laura, Lin, Jessica J., Leyvraz, Serge, Kummar, Shivaani   +14 more
core   +1 more source

NGF-TrkA Axis Enhances PDGF-C-Mediated Angiogenesis in Osteosarcoma via miR-29b-3p Suppression: A Potential Therapeutic Strategy Using Larotrectinib

Life
Angiogenesis plays a critical role in osteosarcoma (OS) growth and metastasis. While nerve growth factor (NGF) is implicated in cancer progression, its role in OS angiogenesis remains unclear.
Sheng-Mou Hou, Ching-Yuan Cheng, Wei-Li Chen, En-Ming Chang, Chih-Yang Lin   +4 more
doaj   +1 more source

Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers

European Thyroid Journal
Context: Two-thirds of metastatic differentiated thyroid cancer (DTC) patients have radioiodine (RAI)-resistant disease, resulting in poor prognosis and high mortality.
Abdul Rehman Syed, Aakash Gorana, Erik Nohr, Xiaoli-Kat Yuan, Parthiv Amin MASc, Sana Ghaznavi, Debbie Lamb, John McIntyre, Markus Eszlinger, Ralf Paschke   +9 more
doaj   +1 more source

Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: a case report

, 2020
NTRK gene-fusions are rare but can occur in diverse cancers. The NTRK inhibitor larotrectinib is newly approved by the FDA. This paper reports the first case of a man with a NTRK-rearranged soft tissue sarcoma treated with larotrectinib in the ...
Kirchgesner, Thomas, Schubert, Thomas, Mazzeo, Filomena, Percy, Catherine, Galant, Christine   +4 more
core  

NTRK1-fusion as an acquired resistance mechanism in EGFRex19 mutated NSCLC: a case report

Frontiers in Pharmacology
IntroductionA 73-year-old Chinese woman with no smoking history was diagnosed with stage IV adenocarcinoma of the lung in August 2020, presenting with left chest pain and multiple lung lesions.Patient concernsThe patient experienced chest pain for 2 ...
Jielin Li, Yunyun Shi, Mengge Zheng, Chenkang Yang, Hong Gao, Xiaoling Li   +5 more
doaj   +1 more source

Supplementary materials: Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers

These are peer-reviewed supplementary materials for the article 'Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers' published in the Journal of Comparative Effectiveness Research ...
Josh Carlson (18499002), Todd Williamson (13278408), Kangho Suh (18498999), Sean Sullivan (1996342), Fang Xia (146439)   +4 more
core   +1 more source

OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation

, 2020
BACKGROUND AND PURPOSE: Larotrectinib is an FDA-approved oral small-molecule inhibitor for treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive cancer.
Afd Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Sparidans, Rolf W, Pharmacoepidemiology and Clinical Pharmacology, Wang, Yaogeng, Schinkel, Alfred H, Pharmacology, Lebre, Maria C, Beijnen, Jos H, Li, Wenlong   +9 more
core  

Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry

Drug Design, Development and Therapy, 2020
Mohamed W Attwa, 1, 2 Adnan A Kadi, 1 Hany W Darwish 1, 3 1Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; 2Students’ University Hospital, Mansoura University, Mansoura 35516, Egypt;
Attwa MW, Kadi AA, Darwish HW
doaj  

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer

, 2019
Introduction: Detecting oncogenic drivers across multiple cancers has brought about a shift toward a more targeted therapeutic approach. Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are genomic rearrangements containing the kinase domain of ...
Noah Federman (799643), Ray McDermott (112352)   +1 more
core   +1 more source